Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC By Ogkologos - October 29, 2025 248 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the cohorts 1 and 2 of the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR When He Said His Mother-In-Law Was Going To Live In The... March 6, 2019 Delivering the future of paediatric brain tumour therapy October 7, 2021 EMA Recommends Extension of Indications for Tislelizumab to First-Line Treatment of... November 19, 2024 Mom Battling Cancer Lets 4-Yr-Old Give Her “Best Haircut Ever.” December 6, 2019 Load more HOT NEWS SABCS 2021: New Research and Updates in Breast Cancer Treatment and... A New Study Suggests Screen Time Might Not Be The Worst... Exercise of Any Intensity Found to Provide Similar Benefits in Cancer... Will politics keep us from accessing EU science funding?
